Press Release
08 |
Dec 2021 |
IntelGenx Initiates Arbitration Proceeding Against Tilray® Related to an Alleged Breach of Worldwide Cannabis-Infused V... |
11 |
Nov 2021 |
IntelGenx Reports Third Quarter 2021 Financial Results... |
04 |
Nov 2021 |
IntelGenx to Report Third Quarter 2021 Financial Results on November 11, 2021 – Conference Call to Follow... |
12 |
Oct 2021 |
Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients wit... |
05 |
Oct 2021 |
IntelGenx Receives Final Approval to Graduate to Toronto Stock Exchange... |
29 |
Sep 2021 |
IntelGenx and Aquestive Therapeutics Partner with Leading Men’s Health Company to Market Tadalafil Oral Films in the U... |
15 |
Sep 2021 |
IntelGenx Receives U.S.$6 Million in Additional Loans from atai Life Sciences and Conditional Approval to Graduate to To... |
07 |
Sep 2021 |
IntelGenx Announces Market Launch of RIZAPORT® in Spain... |
31 |
Aug 2021 |
IntelGenx Ships CBD Filmstrips to Heritage Cannabis in Support of Canadian Market Launch... |
05 |
Aug 2021 |
IntelGenx Announces Closing of Notes Offering... |
04 |
Aug 2021 |
IntelGenx Reports Second Quarter 2021 Financial Results... |
04 |
Aug 2021 |
IntelGenx Strengthens Board with the Appointments of Dr. Srinivas G. Rao and Frank Stegert... |
29 |
Jul 2021 |
IntelGenX to Report Second Quarter 2021 Financial Results on August 4, 2021 – Conference Call to Follow... |
27 |
Jul 2021 |
IntelGenx Announces Subscription for Notes... |
08 |
Jun 2021 |
IntelGenx’s VetaFilm™ Platform to be Evaluated by One of the World’s Fastest Growing Animal Healthcare Companies... |
19 |
May 2021 |
IntelGenx Announces Noteholder Approval of Proposed Amendments to Convertible Notes... |
14 |
May 2021 |
IntelGenx Announces Initial Closing of atai Investment... |
13 |
May 2021 |
IntelGenx Reports First Quarter 2021 Financial Results... |
12 |
May 2021 |
IntelGenx Expands Psychedelics Collaboration with atai Life Sciences with Signing of Second Feasibility Agreement... |
11 |
May 2021 |
IntelGenx Announces Shareholder Approval of atai Investment... |
06 |
May 2021 |
IntelGenx to Report First Quarter 2021 Financial Results on May 13, 2021 – Conference Call to Follow... |
09 |
Apr 2021 |
IntelGenx Announces Intention to Amend Convertible Unsecured Promissory Notes... |
31 |
Mar 2021 |
IntelGenx Ships First CBD Filmstrip Order to Heritage Cannabis... |
25 |
Mar 2021 |
IntelGenx Reports Fourth Quarter and Full-Year 2020 Financial Results... |
18 |
Mar 2021 |
IntelGenx to Report Fourth Quarter and Full-Year 2020 Financial Results on March 25, 2021 – Conference Call to Follow... |
15 |
Mar 2021 |
IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation... |
17 |
Feb 2021 |
IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ™-Based Disintegrating THC Oral Film... |
08 |
Feb 2021 |
IntelGenx Files Provisional U.S. Patent Application for Novel VetaFilm™ High Loading Oral Film Platform... |
12 |
Jan 2021 |
IntelGenx Appoints Tommy Kenny as Vice President, Intellectual Property and Legal Affairs, General Counsel... |
07 |
Jan 2021 |
IntelGenx Receives First Purchase Order For CBD Filmstrips From Heritage Cannabis... |
06 |
Jan 2021 |
IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures... |